151
|
|
152
|
O'Reilly RJ, Brochstein J, Dinsmore R, Kirkpatrick D. Marrow transplantation for congenital disorders. Semin Hematol 1984; 21:188-221. [PMID: 6379881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
153
|
Gardner RV, Gross S. Bone marrow transplantation. Current limitations and future utilization. THE JOURNAL OF THE FLORIDA MEDICAL ASSOCIATION 1984; 71:316-20. [PMID: 6376695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
154
|
Abstract
Bone marrow transplantation in childhood is an established treatment modality for aplastic anemia, the acute and chronic leukemias, and severe combined immune deficiency. Recently, experience with this treatment has also been favorable with small numbers of children who have Wiskott-Aldrich syndrome, several types of inherited storage diseases, Fanconi's anemia, thalassemia, infantile malignant osteopetrosis, and selected cases of lymphoma and other solid tumors. The psychosocial impact and financial costs of bone marrow transplantation can be substantial. Multi-institutional, prospective, randomized trials that would compare transplantation and conventional therapy are necessary to establish the indications and precise timing for this procedure. Further development of monoclonal antibodies, a better understanding of the histocompatibility antigen systems, and improvement in pretransplantation conditioning regimens should increase the spectrum of effectiveness for bone marrow transplantation in the coming years.
Collapse
|
155
|
Schuler D. [Indication and results of bone marrow transplantation in childhood]. Orv Hetil 1984; 125:501-4. [PMID: 6366694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
156
|
Good RA, Kapoor N, Reisner Y. Bone marrow transplantation--an expanding approach to treatment of many diseases. Cell Immunol 1983; 82:36-54. [PMID: 6357489 DOI: 10.1016/0008-8749(83)90139-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Thus, we can conclude that marrow transplantation has already influenced medical practice greatly. It has offered a treatment which often cures patients of more than 20 otherwise lethal diseases. The treatment so horrendously difficult and dangerous at first has already been greatly improved, simplified, and made much safer. The availability of a suitable donor has been much extended and real progress has been made in prevention and perhaps even in treatment of graft-versus-host disease. This has made possible the option of marrow transplantation for every patient in whom we think the treatment may be beneficial. The problem underlying many cases of interstitial pneumonia has been identified and patients are already benefitting clinically from this progress. Progress has also been made which promises antiviral therapy which could reduce, prevent, and ultimately eliminate the intercurrent virus infections which limit the applicability of marrow transplantation, especially for children with severe immunodeficiencies. I do not know how far this line of investigation can be taken. However, just as we have learned stepwise to use marrow transplants from matched siblings to treat many diseases, to use fetal liver in place of bone marrow, to employ matched relative donors when a matched sibling is not available, and, finally, even to use parental donors to achieve correction of SCID, we now have good reason to believe that, ultimately, we can use marrow transplantation without fear of GVHD to address many additional genetically determined and acquired diseases; certainly, for those diseases that involve any of the cells that are derived from bone marrow cells, and perhaps for those attributable even to cells of other organs and tissues, the functions of which are, in whole or in part, a consequence of interactions of marrow-derived cells and cells of ectodermal or endodermal origin, marrow transplantation may be useful. To us, the future of marrow transplantation as a major modality of treatment or prevention of many diseases, including hemoglobinopathesis, immunodeficiencies, hematologic abnormalities, abnormalities of function of marrow-derived cells, and even inborn errors of function of cells of organs and tissues not of marrow origin, seems bright, indeed. Further, with the capacity to introduce resistance genes against viruses and malignancies, autoimmune diseases, and diseases dependent on anomalies of immune response genes, marrow transplantation for many other diseases seems a more remote possibility.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
157
|
Rappeport JM, Smith BR, Parkman R, Rosen FS. Application of bone marrow transplantation in genetic diseases. CLINICS IN HAEMATOLOGY 1983; 12:755-73. [PMID: 6416728 DOI: 10.1016/s0308-2261(83)80009-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
158
|
Kaczmarski M, Taraszkiewicz F, Borowska-Wesław Z, Szałkowska E, Krasowska I. [Wiskott-Aldrich syndrome in children]. PEDIATRIA POLSKA 1983; 58:393-5. [PMID: 6651929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
159
|
Kaczmarski M, Borowska-Wesław Z, Taraszkiewicz F, Szałkowska E, Krasowska I. [Wiskott-Aldrich syndrome in a 2-year-old child]. PEDIATRIA POLSKA 1983; 58:371-3. [PMID: 6634251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
160
|
Ormerod AD, Finlay AY, Knight AG, Mathews N, Stark JM, Gough J. Immune deficiency and multiple viral warts: a possible variant of the Wiskott-Aldrich syndrome. Br J Dermatol 1983; 108:211-5. [PMID: 6824578 DOI: 10.1111/j.1365-2133.1983.tb00065.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
161
|
Ochs HD, Lum LG, Johnson FL, Schiffman G, Wedgwood RJ, Storb R. Bone marrow transplantation in the Wiskott-Aldrich syndrome. Complete hematological and immunological reconstitution. Transplantation 1982; 34:284-8. [PMID: 6760485 DOI: 10.1097/00007890-198211000-00009] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A 21-month-old boy with the Wiskott-Aldrich syndrome conditioned with cyclophosphamide and dimethyl myleran received bone marrow from an HLA-matched sibling. Complete hematological chimerism was achieved. During the first 3 months after transplantation, in vitro B cell function, measured by a direct plaque assay, was abnormal, T cell helper activity impaired, and suppressor T cell function was excessive. These abnormalities resolved gradually over 16 months. Antibody responses to the T-dependent antigen, bacteriophage phi X174, were initially low, then became normal; antibody responses to keyhole limpet hemocyanin (KLH) and to 4 of 12 type-specific pneumococcal polysaccharide antigens were adequate when studied 9 months after transplantation. The clinical response was excellent: the patient has been free of infection, no longer has a bleeding tendency, and has shown normal growth and development.
Collapse
|
162
|
Guss RB, McCulley JP. Abnormal immune responses in the ocular presentation of Wiskott-Aldrich syndrome. ANNALS OF OPHTHALMOLOGY 1982; 14:1058-60. [PMID: 7181336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Wiskott-Aldrich syndrome is an x-linked disorder characterized by a triad of thrombocytopenia, eczema, and recurrent infections. Until recently, survival into the second decade was rare. In the last few years, a better understanding of the syndrome has been achieved, and earlier recognition and newer modes of treatment have improved life. These patients are living longer and ophthalmologic presentation reflects this change. We present three case histories of patients followed for the past 15 years who have had, in association with this syndrome, eczema of the eyelids, episcleritis, marginal keratitis, and blepharitis.
Collapse
|
163
|
Buckley RH. Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem. J Clin Immunol 1982; 2:15S-21S. [PMID: 6806314 DOI: 10.1007/bf00918362] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
164
|
Hutter JJ, Jones JF. Results of a thymic epithelial transplant in a child with Wiskott-Aldrich syndrome and central nervous system lymphoma. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 1981; 18:121-5. [PMID: 7006877 DOI: 10.1016/0090-1229(81)90015-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
165
|
Knutsen AP, Rosse WF, Kinney TR, Buckley RH. Immunologic studies before and after splenectomy in a patient with the Wiskott-Aldrich syndrome. J Clin Immunol 1981; 1:13-9. [PMID: 7334067 DOI: 10.1007/bf00915472] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Sequential studies of cellular and humoral immunity were conducted in an infant with the Wiskott-Aldrich syndrome prior to and after a splenectomy for uncontrollable hemorrhage. All measures of cellular immunity showed gradual improvement during the 8-month period after surgery. Serum isohemagglutinins, diphtheria and tetanus antibodies, and the percentage of immunoglobulin-bearing B cells did not change significantly from presplenectomy values. The serum IgE concentration declined from a high of 10,800 IU/ml at 1 month postsplenectomy to a low of 860 IU/ml at 5 months after surgery and the IgG concentration gradually decreased from a high of 1880 mg/dl presplenectomy to a low of 620 mg/dl 8 months later. The platelet count ranged from 64,000 to 206,000/mm3 for the first 6 months after splenectomy. It decreased precipitously 6.5 months after the operation; at the same time there was a marked rise in platelet-bound IgG antibody (PB-IgG). The PB-IgG declined rapidly following vincristine therapy and, after another rise, declined more gradually following steroid therapy.
Collapse
|
166
|
Fudenberg HH, Wilson GB, Smith CL. Immunotherapy with dialyzable leukocyte extracts and studies of their antigen-specific (transfer factor) activity. PROCEEDINGS OF THE VIRCHOW-PIRQUET MEDICAL SOCIETY 1980; 34:3-87. [PMID: 6270691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
167
|
Spitler LE, Wray BB, Mogerman S, Miller JJ, O'Reilly RJ, Lagios M. Nephropathy in the Wiskott-Aldrich syndrome. Pediatrics 1980; 66:391-8. [PMID: 7422429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Nephropathy was detected in five of 32 patients with the Wiskott-Aldrich syndrome who were participating in a study of transfer factor (TF) therapy. In two patients, nephropathy was present before TF and did not appear changed by TF therapy. One of these patients subsequently developed progressive renal failure requiring dialysis beginning 5 1/2 years after TF therapy. In two patients, decreased renal function appeared very soon after the administration of TF. One patient showed gradually decreasing renal function beginning after two years of TF therapy. An additional patient was identified who died with renal failure without having received TF. The results suggest that renal failure occurs in the Wiskott-Aldrich syndrome more frequently than generally recognized and that administration of TF may precipitate or accelerate the renal disease in patients with this syndrome.
Collapse
|
168
|
Zduńczyk A. [Transfer factor (its use in immunotherapy of neoplasms and other diseases)]. WIADOMOSCI LEKARSKIE (WARSAW, POLAND : 1960) 1980; 33:877-81. [PMID: 6999743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
169
|
|
170
|
Lum LG, Tubergen DG, Corash L, Blaese RM. Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome. N Engl J Med 1980; 302:892-6. [PMID: 6767187 DOI: 10.1056/nejm198004173021604] [Citation(s) in RCA: 105] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The Wiskott-Aldrich syndrome is an X-linked immunodeficiency disorder consisting of the triad of frequent infections, eczema, and profound thrombocytopenia. We evaluated the effects of splenectomy on hemostatic improvement and subsequent clinical course in 16 patients with the Wiskott-Aldrich syndrome. All 16 had an increase in platelet counts to at least 100,000 per cubic millimeter after splenectomy, with the mean increasing from 19,900 per cubic millimeter preoperatively to 262,700 per cubic millimeter after splenectomy. In addition, platelet size, which is characteristically small in this disease, also became normal. Survival after splenectomy correlated with the prophylactic use of antibiotics. Five of seven patients not taking prophylactic antibiotics died of sepis within 33 months of surgery. The mean survival of the nine patients maintained with prophylactic antibiotics, however, was at least 91.4 months, with six of these patients still alive an average of 11.0 years or more after splenectomy. Thus, splenectomy is a useful therapy for a major cause of morbidity and mortality in this complex syndrome.
Collapse
|
171
|
Perino KE, James RB. Wiskott-Aldrich syndrome: review of literature and report of case. JOURNAL OF ORAL SURGERY (AMERICAN DENTAL ASSOCIATION : 1965) 1980; 38:297-303. [PMID: 6928459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Wiskott-Aldrich syndrome has been described. Other reports and studies of the syndrome have been compiled. Discussion of the incompletely understood pathogenesis and current treatment modalities are included with a differential diagnosis of related conditions. Although this syndrome is uncommon, it is not rare. The patient's susceptibility to infection and propensity to bleed makes early recognition and vigorous treatment an important and challenging task. It is hoped that this report will foster awareness of such patients and the complications involved in treatment.
Collapse
|
172
|
Schindler TE, Baram P. Transfer factor: specific and nonspecific effects and chemical characteristics of dialyzable leukocyte lysates (DLL). Part II. Reconstituting effects dialyzable leukocyte lysates. (Second of three parts). Allergol Immunopathol (Madr) 1980; 8:125-9. [PMID: 7457287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
173
|
Endre L, Nékám K, Osváth P, Nagy M, Károly U, Uhl K. [Successful treatment of Wiscott-Aldrich syndrome with transfer factor]. Orv Hetil 1979; 120:2361-6. [PMID: 392396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
174
|
Pahwa R, Ikehara S, Pahwa SG, Good RA. Thymic function in man. THYMUS 1979; 1:27-58. [PMID: 317931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
175
|
Abstract
Thirty-two patients with the Wiskott-Aldrich syndrome have been treated with transfer factor provided by this laboratory. Apparent clinical benefit was observed in 44 per cent of them. The mean age of the patients who showed clinical benefit was significantly greater than that of the patients who showed no benefit. Conversion of immunologic reactivity correlated with clinical benefit. Thirteen of the patients who received transfer factor are alive, and 17 have died (43 per cent survival). Clinical benefit was correlated with survival. The median survival was greater than five years in the patients who showed clinical benefit, whereas it was 18 months in those who did not show clinical benefit. We conclude that transfer factor caused conversion of immunologic parameters, apparent clinical benefit and prolonged survival in some, but not all, patients with the Wiskott-Aldrich syndrome.
Collapse
|
176
|
Láng I, Nékám K, Török K, Gergely P. [Changes in the antibody dependent cytotoxicity under the effect of transfer factor therapy. Preliminary report]. Orv Hetil 1979; 120:1491-5. [PMID: 471469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
177
|
Di Padova F. [A new approach to immunotherapy: the transfer factor]. Minerva Med 1979; 70:1773-85. [PMID: 379697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The transfer factor is a tiny molecule capable of transferring the function of the T lymphocytes (immunological memory and retarded hypersensitivity) from a sensitized to a non-sensitized individual. The exact structure and action modalities of the molecule have not yet been precisely established. The difficulties involved in the study of the transfer factor are aggravated by the lack of any suitable experimental model. The attention of immunologists is attracted by this factor which opens up new prospects for the treatment of cancer, immunological deficiencies and certain infectious and autoimmune diseases. More profound research would appear useful to evaluate if and in what cases a potentiation of the immune mechanism can represent an alternative to immunosuppression.
Collapse
|
178
|
Schut BJ, Dooren LJ, Uittenbogaart CH, Schellekens PT, Eijsvoogel VP. Cellular immunity in patients with the Wiskott-Aldrich syndrome before and after administration of transfer factor: a follow-up study. Immunology 1979; 36:1-12. [PMID: 369991 PMCID: PMC1457393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Four patients with Wiskott-Aldrich syndrome were treated with transfer factor (TF), in an attempt to improve their clinical condition. Before and during treatment, cellular reactivity was followed in vivo (delayed type skin reactivity) and in vitro (lymphocyte transformation). In all patients positive skin reactions were occasionally observed during TF treatment. The lymphocyte reactivity in vitro to phytohaemagglutinin (PHA) was slightly diminished, the responding capacity of the mixed lymphocyte culture (MLC) severely impaired and the response to bacterial, viral and fungal antigens absent before and during TF treatment. No clinical improvement was observed after large doses of TF. No correlation between skin test reversal and TF administration was found, and lymphocyte transformation in vitro did not improve. Subsequently, a double blind trial, in which we compared the effect of TF and placebo, was carried out in these patients, which revealed no effect of TF therapy. It is concluded that the results of treatment with TF in these patients are highly controversial.
Collapse
|
179
|
Mackie RM, Alcorn MJ, Stevenson RD, Cochran T, McSween RN. Wiskott-Aldrich syndrome with partial response to transfer factor. Br J Dermatol 1978; 98:567-71. [PMID: 656329 DOI: 10.1111/j.1365-2133.1978.tb01944.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
A male infant presented with dermatitis, purpura and susceptibility to bacterial infections. The clinical diagnosis of Wiskott-Aldrich syndrome was confirmed and after full immunological assessment, treatment with transfer factor was commenced. This has resulted in a rise in the platelet count and improvement in the bleeding tendency. This improvement in the haematological aspect of the disease has, however, been accompanied by exacerbations of the cutaneous lesions.
Collapse
|
180
|
|
181
|
Parkman R, Rappeport J, Geha R, Belli J, Cassady R, Levey R, Nathan DG, Rosen FS. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N Engl J Med 1978; 298:921-7. [PMID: 347289 DOI: 10.1056/nejm197804272981701] [Citation(s) in RCA: 201] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Two patients with the Wiskott-Aldrich syndrome had complete donor lymphoid and hematopoietic engraftment after successful allogeneic bone-marrow transplantation. One patient had had only a temporary donor T-lymphocyte graft after a previous transplantation, for which he had been prepared with cytarabine and cyclophosphamide; the patient's own T lymphocytes returned six months later. A repeat transplant, for which the patient was prepared with anti-human thymocyte serum, total-body irradiation and procarbazine, resulted in complete donor engraftment. The second patient underwent a successful transplantation after similar preparation, except that procarbazine was omitted. At 11 and five months after transplantation both had normal hematopoiesis and no evidence of graft-versus-host disease. This treatment of the Wiskott-Aldrich syndrome may be a model for the correction of other genetically determined immune and hematologic bone-marrow disorders.
Collapse
|
182
|
Medunitsyn NV. ["Transfer factor". Experimental findings and prospects for its clinical use]. PATOLOGICHESKAIA FIZIOLOGIIA I EKSPERIMENTAL'NAIA TERAPIIA 1977:75-80. [PMID: 325478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
183
|
Kraj M, Cieśluk S. [Therapeutic prospects in some immune deficiency syndromes and other pathological conditions connected with immune disorders]. ACTA HAEMATOLOGICA POLONICA 1976; 7:327-35. [PMID: 793282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
184
|
Kobielowa Z. [Treatment of immunologic deficiency conditions by means of transfer factor]. PEDIATRIA POLSKA 1975; 50:1393-7. [PMID: 1103073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
185
|
Stevens DA, Ferrington RA, Merigan TC, Marinkovich VA. Randomized trial of transfer factor treatment of human warts. Clin Exp Immunol 1975; 21:520-4. [PMID: 1106927 PMCID: PMC1538314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Dialysed transfer factor, prepared from the leucocytes of a donor whose warts had undergone recent spontaneous regression, was used in the treatment of a child with the Wiskott--Aldrich syndrome. The child then had a spontaneous regression at multiple warty areas. A similar relationship was seen in four otherwise healthy patients in a pilot study. A randomized double-blind study of thirty patients failed to confirm a causal relationship between the transfer factor therapy (equivalent to 2-1 X 10(8) leucocytes) and wart regressions. The need for randomized trials of transfer factor therapy for diseases with a variable natural history is emphasized.
Collapse
|
186
|
MESH Headings
- Anemia, Aplastic/therapy
- Anemia, Hemolytic, Autoimmune/immunology
- Anemia, Hemolytic, Autoimmune/therapy
- Autoantibodies/analysis
- Elliptocytosis, Hereditary/therapy
- Female
- Hematologic Diseases/therapy
- Hodgkin Disease/pathology
- Humans
- Laparotomy
- Leukopenia/therapy
- Lupus Erythematosus, Systemic/therapy
- Lymphoma/pathology
- Male
- Purpura, Thrombocytopenic/diagnosis
- Purpura, Thrombocytopenic/therapy
- Purpura, Thrombotic Thrombocytopenic/therapy
- Spherocytosis, Hereditary/therapy
- Splenectomy
- Splenic Rupture/surgery
- Syndrome
- Thrombocytopenia/genetics
- Thrombocytopenia/surgery
- Wiskott-Aldrich Syndrome/therapy
Collapse
|
187
|
Shabalov NP. [Wiskott-Aldrich syndrome (literature review)]. VOPROSY OKHRANY MATERINSTVA I DETSTVA 1975; 20:50-4. [PMID: 1094723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
188
|
|
189
|
|
190
|
Rosenthal M. [Transfer factor and its therapeutic use]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT 1974; 104:1501-6. [PMID: 4549135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
191
|
Mutz I, Lankford J, Humphrey GB. Biologic and clinical implications of transfer factor. South Med J 1974; 67:837-40. [PMID: 4599982 DOI: 10.1097/00007611-197407000-00021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
192
|
Dupont B, Ballow M, Hansen JA, Quick C, Yunis EJ, Good RA. Effect of transfer factor therapy on mixed lymphocyte culture reactivity. Proc Natl Acad Sci U S A 1974; 71:867-71. [PMID: 4274562 PMCID: PMC388116 DOI: 10.1073/pnas.71.3.867] [Citation(s) in RCA: 42] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
We have studied the effect of dialyzable transfer factor therapy on three patients with immunodeficiency disease and in one patient who demonstrated no evidence of deficiency of either humoral or cellular immunity. We found evidence for nonspecificity in the effect of transfer factor on mixed lymphocyte culture reactivity. The data suggest that in patients with immunodeficiency disease a maturation of lymphocytes may lead to a generalized increased immune responsiveness. More profoundly, our data show that transfer factor may induce changes in the expression of histocompatibility determinants. We observed changes in the expression of determinants capable of stimulating in the mixed lymphocyte culture reaction as well as an increase in the capacity of lymphocytes to respond.
Collapse
|
193
|
Francke C, Grob PJ. [Transfer factor therapy. Preliminary report]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT 1974; 104:146-7. [PMID: 4811475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
194
|
|
195
|
Ballow M, Dupont B, Good RA. Autoimmune hemolytic anemia in Wiskott-Aldrich syndrome during treatment with transfer factor. J Pediatr 1973; 83:772-80. [PMID: 4742570 DOI: 10.1016/s0022-3476(73)80368-3] [Citation(s) in RCA: 45] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
196
|
Millikan LE. Wiskott Aldrich syndrome: a treatable immune disorder. A review. MISSOURI MEDICINE 1973; 70:764-7 passim. [PMID: 4591682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
197
|
Griscelli C, Herzog C, Mozziconacci P. [Wiskott-Aldrich syndrome. Recent information apropos of 4 cases]. NOUVELLE REVUE FRANCAISE D'HEMATOLOGIE 1973; 13:554-68. [PMID: 4271105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
198
|
Heyn RM, Tubergen DG, Althouse NT. Lymphocyte size distribution. Determination in normal children and adults and in patients with immunodeficiency states. AMERICAN JOURNAL OF DISEASES OF CHILDREN (1960) 1973; 125:789-93. [PMID: 4575238 DOI: 10.1001/archpedi.1973.04160060007002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
199
|
Griscelli C, Revillard JP, Betuel H, Herzog C, Touraine JL. Transfer factor therapy in immuno-deficiencies. BIOMEDICINE / [PUBLIEE POUR L'A.A.I.C.I.G.] 1973; 18:220-7. [PMID: 4742861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
200
|
|